🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating globally, with estimates suggesting over 82 million instances each year. Especially elevated rates are seen in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization represents a major breakthrough in the management of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Results and Global Access

According to data published in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which uses a dual-drug approach. The study involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to make available and distribute the drug in many low-income and middle-income countries.

Clinicians directly involved have voiced hope. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for managing the epidemic. This is deemed essential to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea globally.